John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.
John Haanen, MD, PhD
Advertisement
Articles by John Haanen, MD, PhD
Advertisement
Latest Updated Articles
Dr. John Haanen on the Role of PD-L1 in Lung CancerPublished: April 14th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5